Share
   
Title
Code
Session Type
Venue
Date Time
Co-Chairs:

Daily use of PrEP has proved to be a very effective tool in preventing HIV when taken consistently, with many countries adopting the new WHO guidelines on oral daily PrEP with emtricitabine/tenofovir. However, many studies have cited an inability to take a daily pill by some sub-populations as contributing to low adherence among these groups. Additionally, potential toxicity with systemic PrEP may also affect PrEP efficacy. As a result, a wide range of dosage forms of topical PrEP agents are needed as PrEP as a prevention tool evolves. This symposium, aimed at researchers, clinicians and healthcare providers, community workers and people using PrEP, explores the pharmacology, different delivery forms and adherence/acceptability challenges of topical PrEP.

11:00
MOSY0301
Introduction
Raphael Landovitz, Center for Clinical AIDS Research & Education, United States
11:05
MOSY0302
Does pharmacology support topical PrEP?
Angela Kashuba, University of North Carolina, United States
Slides
11:15
MOSY0303
Lessons learnt from tenofovir vaginal gel studies
Salim Abdool Karim, Centre for the AIDS Programme of Research in South Africa (CAPRISA), South Africa
Slides
11:25
MOSY0304
Intra-vaginal rings for PrEP: what are the future prospects?
Annalene Nel, International Partnership for Microbicides (IPM), United States
Slides
11:35
MOSY0305
Rectal gels for PrEP: are they an option?
Ian McGowan, University of Pittsburgh, United States
Slides
11:45
MOSY0306
Adherence and acceptability challenges with topical PrEP
Jessica Haberer, Massachusetts General Hospital (MGH), United States
Slides
11:55
MOSY0307
Questions and answers
12:25
MOSY0308
Closing remarks
Jared Baeten, University of Washington, United States
Slides